Posted on

ROVI reports operating revenue growth of 57% and net profit growth of 123%

ROVI has published the financial results recorded in the first quarter of 2022. Among the main indicators obtained, the following stand out:

  • Operating revenue increased by 57% to 205.6 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 167%, and (ii) the specialty pharmaceutical business, where sales rose 16%.
  • EBITDA increased by 113% to 74.3 million euros and Net profit increased by 123% to 53.0 million euros. 
  • Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 19% to 75.9 million euros.
  • Sales of prescription-based pharmaceutical products rose 17% to 100.5 million euros in the first quarter of 2022.
  • Sales of the enoxaparin biosimilar increased 50% to 44.2 million euros in the first quarter of 2022 mainly because of (i) the launch of the product in four new countries in the first quarter of 2022 and (ii) the increase in the demand for the product in countries where we are already present.
  • In April, Okedi® (Risperidone ISM®) was launched in Germany for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

ROVI is in a new phase of growth, supported by the strength of the third-party manufacturing business and the pharmaceutical specialties business, and exptects its operating revenue to increase by between 15% and 20% for 2022.

Posted on

Learn more about the SA 8000 at ROVI

SA8000 is a voluntary certification based on international agreements aimed at improving the working conditions of all employees of the company, as well as suppliers and subcontractors.

With this certification, ROVI undertakes to comply with a series of essential requirements in terms of social justice and workers’ rights. SA8000 at ROVI is based on 6 points that you should be aware of.

Find out the 1st point about SA 8000 at ROVI: Against child, forced and compulsory labour.

Posted on

World day for safety and health at work

Because there is nothing more important than health and safety

At ROVI, we continue to work on building a positive health and safety culture among our employees. The COVID-19 pandemic has shown the importance of having a sound occupational health and safety system in which all the employees participate. It is the only way for ROVI to remain a space where the well-being of all its workers is assured.

Our strategy to create a culture of awareness of the importance of looking after health and safety at work rests on two basic pillars:

Occupational Risk Prevention (ORP) training

ROVI works with continuing ORP training, which begins when the employee joins the company and continues throughout their professional career with ROVI. This training covers subjects so important as the use of PPE, guidelines for emergencies, ways to avoid injury and rules on accident prevention. The system forms part of an annual training plan, the goal of which is not only to reduce the company’s accident rate, but also to raise employees’ awareness of the importance of protecting health and safety at work.

Near Miss report

To help us improve, at ROVI we have put in place the Near Miss report to report potentially dangerous situations. This document has been distributed by the plants so that any employee can report situations that could lead to an accident directly to the Health and Safety Department. These situations will be studied by the Department and, where necessary, the corrections or improvements necessary to avoid any accident will be made.

This direct communication by the employees is of vital importance. Your contributions help us to strengthen our Occupational Health and Safety System. We are counting on you.